Form 4 for SNDX Syndax Pharmaceuticals Inc
Accepted 2025-05-19 00:00:00 ET · period of report 2025-05-19 · accession 0000950170-25-074304 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-19 | 2025-05-19 | SNDX | Goldan Keith A. | CFO | P - Purchase | — | +3,000 | 93.7K | +3% | — |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-05-19 | P | A | 3,000 | — | 93,746 | D | — | — | (F1) The purchase prices ranged from $8.8465 to $9.2825. |